HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gaya K Amarasinghe Selected Research

Ebola virus nucleoprotein VP35

7/2013Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gaya K Amarasinghe Research Topics

Disease

15Infections
06/2022 - 09/2009
6COVID-19
01/2022 - 11/2020
4Virus Diseases (Viral Diseases)
01/2017 - 06/2012
2Pneumonia (Pneumonitis)
01/2022 - 01/2018
2Inflammation (Inflammations)
01/2022 - 01/2018
2Respiratory Syncytial Virus Infections
10/2021 - 01/2021
1Ebola Hemorrhagic Fever
01/2021
1Severe Fever with Thrombocytopenia Syndrome
01/2020
1Persistent Infection
12/2019
1Foodborne Diseases
10/2019
1Septic Shock (Toxic Shock Syndrome)
10/2019
1Tuberculosis (Tuberculoses)
10/2018
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2018
1Bacterial Infections (Bacterial Infection)
01/2018
1Ataxia Telangiectasia (Louis Bar Syndrome)
01/2018
1Parkinson Disease (Parkinson's Disease)
01/2018
1Retroviridae Infections (Infection, Retrovirus)
01/2018
1Dysbiosis
01/2018
1Melanoma (Melanoma, Malignant)
12/2012

Drug/Important Bio-Agent (IBA)

11Proteins (Proteins, Gene)FDA Link
01/2022 - 07/2013
5Antiviral Agents (Antivirals)IBA
01/2022 - 01/2011
4Neutralizing AntibodiesIBA
01/2022 - 12/2020
4InterferonsIBA
01/2021 - 02/2014
4RNA (Ribonucleic Acid)IBA
01/2018 - 06/2012
3AntibodiesIBA
01/2022 - 01/2021
3VaccinesIBA
01/2022 - 01/2022
3CytokinesIBA
01/2022 - 09/2009
3Pharmaceutical PreparationsIBA
01/2021 - 10/2018
3Viral RNAIBA
01/2021 - 01/2013
2Viral ProteinsIBA
01/2022 - 11/2020
2EpitopesIBA
01/2022 - 10/2019
2Pathogen-Associated Molecular Pattern MoleculesIBA
01/2018 - 12/2012
2Interferon Type IIBA
01/2017 - 01/2016
1Biomarkers (Surrogate Marker)IBA
06/2022
1Glycoproteins (Glycoprotein)IBA
06/2022
1Indicators and Reagents (Reagents)IBA
01/2022
1Monoclonal AntibodiesIBA
01/2022
1SARS-CoV-2 spike proteinIBA
01/2022
1Peptides (Polypeptides)IBA
01/2022
1Interleukin-6 (Interleukin 6)IBA
01/2022
1Interleukin-8 (Interleukin 8)IBA
01/2022
1Protein SIBA
01/2022
1Virulence Factors (Pathogenicity Factors)IBA
01/2022
1Transcription Factors (Transcription Factor)IBA
10/2021
1ChromatinIBA
10/2021
1Heterogeneous-Nuclear Ribonucleoprotein LIBA
01/2021
1Tyrosine (L-Tyrosine)FDA Link
01/2021
1glucose-regulated proteinsIBA
01/2021
1Proline (L-Proline)FDA Link
01/2021
1Heat-Shock Proteins (Heat-Shock Protein)IBA
01/2021
1mouse Lrp1 proteinIBA
01/2021
1Nucleocapsid ProteinsIBA
11/2020
1Protein CIBA
11/2020
1Viral Nonstructural ProteinsIBA
12/2019
1Immunoglobulin G (IgG)IBA
10/2019
1Biological Warfare AgentsIBA
10/2019
1staphylococcal enterotoxin BIBA
10/2019
1Rifampin (Rifampicin)FDA LinkGeneric
10/2018
1Amyloid (Amyloid Fibrils)IBA
01/2018
1OzoneIBA
01/2018
1alpha-SynucleinIBA
01/2018
1Phosphotransferases (Kinase)IBA
01/2018
1RNA CapsIBA
01/2018
1Discoidin Domain ReceptorsIBA
01/2018
1lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA
01/2018
1O- (5- O- (4- coumaroyl)- alpha- arabinofuranosyl)- (1- 3)- O- beta- xylopyranosyl- (1- 4)- xylopyranoseIBA
01/2018
1Amyloidogenic ProteinsIBA
01/2018
1CaspasesIBA
01/2018
1ElementsIBA
01/2018
1DNA (Deoxyribonucleic Acid)IBA
01/2018
1Tolcapone (Tasmar)FDA Link
10/2017
1alpha KaryopherinsIBA
01/2017
1Pattern Recognition ReceptorsIBA
01/2016
1Ebola virus nucleoprotein VP35IBA
07/2013
1ThapsigarginIBA
01/2013
14-O-carboxymethylascochlorinIBA
01/2013
1Marburg virus VP24 proteinIBA
09/2009

Therapy/Procedure

3Therapeutics
01/2022 - 12/2020